Characterization of drug efflux transporters at the blood-brain and blood-spinal cord barriers in an ALS SOD1 rat model. P-glycoprotein transport activity and expression levels were increased at the CNS barriers in rats at the ALS symptomatic stage. P-glycoprotein induction can restrict CNS delivery of current and new ALS pharmacotherapies that are substrates for this transporter.